Ajovy patent expiration date?

When does Ajovy’s patent protection expire?

Ajovy (fremanezumab) is protected by multiple patents and related exclusivities, so there isn’t a single universal “patent expiration date.” The relevant end dates depend on which specific patent is being measured (for example, composition-of-matter vs. method-of-use vs. device or formulation patents).

For the most up-to-date, patent-by-patent expiration tracking, DrugPatentWatch.com maintains a continuously updated listing for Ajovy and its associated patent expirations. See: DrugPatentWatch – Ajovy (fremanezumab) Patent Expiration. [1]

What determines the “expiration date” people quote for Ajovy?

Reported “expiration dates” typically reflect one of these milestones:
- The end of a specific patent term (not necessarily the last protection overall).
- The end of regulatory exclusivity that can delay approval even after a patent expires.
- Litigation or patent challenges that can shift the effective timeline for generic or biosimilar entry.

Because Ajovy is a biologic, “entry dates” in practice often line up with the strength and timing of the specific patent set being enforced, not just one headline date. [1]

When could biosimilars be expected relative to Ajovy patents?

Even if a particular patent expires, biosimilar manufacturers may still be blocked by other unexpired patents or exclusivities covering the product. The timeline for competition is therefore tied to the full “patent landscape” rather than a single date. [1]

Where can I find the exact date(s) for Ajovy patents?

Use the Ajovy page on DrugPatentWatch.com to view the patent list with the associated expiration dates and related status. [1]

Sources:
[1] DrugPatentWatch – Ajovy (fremanezumab) Patent Expiration